XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a dopamine D2 receptor partial agonist, a dopamine D3 receptor antagonist, an α1A-adrenergic receptor antagonist, and a serotonin 5-HT1B, 5-HT2A, and 5-HT2B receptor antagonist. Its potency as a dopamine D2 receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals. Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D3 agonism), vasoconstriction (related to α1A-adrenergic and 5-HT1B agonism), hallucinogenic effects (related to 5-HT2A agonism), and cardiac valvulopathy (related to 5-HT2B agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride. The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile. XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.
See also List of investigational Parkinson's disease drugs XC-101-D13H (XC-101)
References
External links Pipeline - Xoc Pharmaceuticals